tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta pseudogene 7Genealiases: []
Q-omics provides the consensus-scored YWHAZP7 profile across patient tissues and cancer cell-line models. YWHAZP7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, YWHAZP7 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, YWHAZP7 RNA expression shows 5,937 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, HNSC, and STAD as cancer lineages where YWHAZP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YWHAZP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YWHAZP7 survival associations across molecular data types. YWHAZP7 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YWHAZP7 RNA expression–survival associations across cancer types. High YWHAZP7 expression shows unfavorable associations in KICH, UCEC, UVM, MESO and LUAD, but favorable associations in LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for YWHAZP7 RNA expression.
This table summarizes YWHAZP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for YWHAZP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YWHAZP7 shows higher tumor expression in HNSC, BRCA and BLCA. The HNSC box plot shows higher YWHAZP7 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .030).
This table shows molecular features associated with YWHAZP7 in patient tissues and cancer cell lines. In patient samples, YWHAZP7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
